|

PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • UNC Lineberger Comprehensive Cancer Center1

Indications

  • Metastatic Head and Neck Cancer1
  • Resectable Head and Neck Squamous Cell Carcinoma1
  • Metastatic Squamous Cell Carcinoma1
  • Metastatic Lung Cancer1
  • Head and Neck Cancer1

Chapel Hill, North Carolina1 trial

Effects of Infusion Timing on Treatment Response in Solid Tumors

University of North Carolina at Chapel Hill, Department of Radiation Oncology

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.